Uzbekistan and Novel Therapeutics Technology Discuss Cooperation

Tashkent, Uzbekistan (UzDaily.com) — On 4 December 2025, a meeting was held at the agency building with representatives of Novel Therapeutics Technology.

Founded in 2020, the company specializes in developing pharmaceuticals using artificial intelligence, conducts biotechnology research, and produces drugs primarily focused on oncology and neurology.

During the meeting, both sides presented their areas of activity. Representatives of Novel Therapeutics Technology highlighted the work of the TMC3 Collaboration Center in Houston, USA, and emphasized that potential cooperation could be mutually beneficial.

The agency, in turn, briefed the guests on the operating conditions and incentives available within the Tashkent Pharma Park pharmaceutical cluster, as well as ongoing projects and opportunities being created for investors and researchers.

As a result of the discussions, both parties agreed to further develop cooperation and exchange expertise in education, scientific research, and the application of artificial intelligence.